SCOPUS 정보 검색 플랫폼

Volumn 3, Issue 2, 2006, Pages 131-139

The case of the disappearing polymorph: 'Inherent anticipation' and the impact of SmithKline Beecham Corp. v Apotex Corp. (Paxil®) on patent validity and infringement by inevitable conversion

(2) Rakoczy, William A a Mazzochi, Deanne M a

a Rakoczy Molino Mazzochi Siwik LLP (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; GENERIC DRUG; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TERAZOSIN;

ARTICLE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; HUMAN; JURISPRUDENCE; LAW SUIT; LEGAL ASPECT; MEDICAL DOCUMENTATION; PATENT; UNITED STATES;

EID: 33751564845 PISSN: 17411343 EISSN: 17417090 Source Type: Journal
DOI: 10.1057/palgrave.jgm.4940110 Document Type: Article

Times cited : (5)

References (18)

1
- 33751577044
- SmithKline Beecham Corp. v Apotex Corp
- 925, (ND III.)
- SmithKline Beecham Corp. v Apotex Corp., 286 F. Supp. 2d 925, 940 (ND III. 2001).
- (2001) F. Supp. 2d , vol.286 , pp. 940

2
- 33751583998
- SmithKline Beecham Corp. v Apotex Corp
- Ref. 1 above at 937-38.
- (2001) F. Supp. 2d , vol.286 , pp. 937-938

3
- 33751556203
- SmithKline Beecham Corp. v Apotex Corp
- 1011, (ND III.)
- See SmithKline Beecham Corp. v Apotex Corp., 247 F. Supp. 2d 1011, 1052 (ND III. 2003).
- (2003) F. Supp. 2d , vol.247 , pp. 1052

4
- 33751576185
- Cont'l Plastic Containers v Owens Brockway Plastic Prods., Inc
- 1073, (Fed. Cir.)
- See Cont'l Plastic Containers v Owens Brockway Plastic Prods., Inc., 141 F.3d 1073, 1079 (Fed. Cir. 1998).
- (1998) F.3d , vol.141 , pp. 1079

5
- 33751580898
- SmithKline Beecham Corp. v Apotex Corp
- 1306, (Fed. Cir.)
- SmithKline Beecham Corp. v Apotex Corp., 365 F.3d 1306, 1318-20 (Fed. Cir. 2004).
- (2004) F.3d , vol.365 , pp. 1318-1320

6
- 33751564090
- SmithKline Beecham Corp. v Apotex Corp
- 1331, (Fed. Cir.)
- SmithKline Beecham Corp. v Apotex Corp., 403 F.3d 1331, 1346 (Fed. Cir. 2005).
- (2005) F.3d , vol.403 , pp. 1346

7
- 33751564090
- SmithKline Beecham Corp. v Apotex Corp
- Ref. 6 above at 1343.
- (2005) F.3d , vol.403 , pp. 1343

8
- 33751564090
- SmithKline Beecham Corp. v Apotex Corp
- Ref. 6 above at 1344.
- (2005) F.3d , vol.403 , pp. 1344

9
- 33751564090
- SmithKline Beecham Corp. v Apotex Corp
- Ref. 6 above at 1345-46.
- (2005) F.3d , vol.403 , pp. 1345-1346

10
- 33751564090
- SmithKline Beecham Corp. v Apotex Corp
- Ref. 6 above at 1345.
- (2005) F.3d , vol.403 , pp. 1345

11
- 33751565018
- Glaxo, Inc v Novopharm, Ltd
- Ref. 6. This theory had also been advanced by GSK in previous litigation relating to the formation of the Form II polymorph of ranitidine hydrochloride (Zantact®) 871, (EDNC)
- Ref. 6. This theory had also been advanced by GSK in previous litigation relating to the formation of the Form II polymorph of ranitidine hydrochloride (Zantact®). See Glaxo, Inc v Novopharm, Ltd, 830 F. Supp. 871, 875-76 (EDNC 1993).
- (1993) F. Supp. , vol.830 , pp. 875-876

12
- 33751566821
- SmithKline
- SmithKline, 403 F.3d at 1345.
- F.3d , vol.403 , pp. 1345

13
- 77950131144
- Ortho-McNeil Pharm., Inc. v Mylan Labs., Inc
- (ND W. Va.)
- See Ortho-McNeil Pharm., Inc. v Mylan Labs., Inc., 348 F. Supp. 2d 713 (ND W. Va. 2004).
- (2004) F. Supp. 2d , vol.348 , pp. 713

14
- 33751566821
- SmithKline
- SmithKline, 403 F.3d at 1345.
- F.3d , vol.403 , pp. 1345

15
- 33751563475
- Atlas Powder
- See Atlas Powder, 190 F.3d at 1347.
- F.3d , vol.190 , pp. 1347

16
- 33751563475
- Atlas Powder
- Ref. 15 at 1346 (internal citation omitted)
- Ref. 15 at 1346 (internal citation omitted)
- F.3d , vol.190 , pp. 1347

17
- 84887353749
- Schering
- Schering, 339 F.3d at 1381.
- F.3d , vol.339 , pp. 1381

18
- 33751565705
- Merck & Co. v Teva Pharms
- 1364 4USA, Inc. (Fed. Cir.)
- See Merck & Co. v Teva Pharms. USA, Inc., 395 F.3d 1364, 1377 (Fed. Cir. 2005).
- (2005) F.3d , vol.395 , pp. 1377

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.